LABELS · 5b2d0f4e-5bba-4048-a2f0-bcb4b779efc0

Verzenio

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date: 2026-07-13
Captured: 2026-09-09T23:37:47.659725+00:00
Current indication reconciliation: Not reconciled

Indications and usage: exact source text

1 INDICATIONS AND USAGE VERZENIO ® is a kinase inhibitor indicated: in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of recurrence. ( 1.1 , 14.1 ) in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. ( 1.2 ) in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. ( 1.2 ) as monotherapy for the treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting. ( 1.2 ) 1.1 Early Breast Cancer VERZENIO ® (abemaciclib) is indicated: in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of recurrence [see Clinical Studies ( 14.1 )]. 1.2 Advanced or Metastatic Breast Cancer VERZENIO (abemaciclib) is indicated: in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. as monotherapy for the treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.

Full extracted label fields

application numbers

NDA208716

boxed warning exact

brand names

Verzenio

current indication status

not_reconciled

dailymed set url

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=be4bc0de-0fdc-4d46-8d25-be43c79e6a06

generic names

ABEMACICLIB

5b2d0f4e-5bba-4048-a2f0-bcb4b779efc0

indications and usage exact

1 INDICATIONS AND USAGE VERZENIO ® is a kinase inhibitor indicated: in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of recurrence. ( 1.1 , 14.1 ) in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. ( 1.2 ) in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. ( 1.2 ) as monotherapy for the treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting. ( 1.2 ) 1.1 Early Breast Cancer VERZENIO ® (abemaciclib) is indicated: in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of recurrence [see Clinical Studies ( 14.1 )]. 1.2 Advanced or Metastatic Breast Cancer VERZENIO (abemaciclib) is indicated: in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. as monotherapy for the treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.

indications and usage tables exact

is original packager

true

manufacturer names

Eli Lilly and Company

matched search terms

cancer

package ndcs

0002-4483-54
0002-4483-62
0002-4815-54
0002-4815-62
0002-5337-54
0002-5337-63
0002-5337-62
0002-6216-54

product ndcs

0002-4483
0002-4815
0002-5337
0002-6216

product types

HUMAN PRESCRIPTION DRUG

recent major changes exact

record type

complete_spl_indications_section_candidate

routes

ORAL

rxcuis

1946830
1946836
1946838
1946840
1946842
1946844
1946846
1946848

source batch

file

/private/tmp/cancer-full-research/indications/raw/labels-00300.json

Source passages and status connections

Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

Passage 1 · positive indication candidate

application numbers

NDA208716

brand names

Verzenio

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement
positive_statement_also_contains_qualification_review_required

clinical review status

pending

content role

positive_indication_candidate

context span

end: 546
end exclusive: true
exact text: 1 INDICATIONS AND USAGE VERZENIO ® is a kinase inhibitor indicated: in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of recurrence. ( 1.1 , 14.1 ) in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor rec
label id: 5b2d0f4e-5bba-4048-a2f0-bcb4b779efc0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f68ed7c4d30314c0e63657bc67b4f9a830de4cb553a2492a05e9ea160d7e4e27
start: 0

current approval status

not_reconciled

duplicate text group

dup-78f6abb92959f73012bb

extraction review status

automated_candidate_pending_source_review

generic names

ABEMACICLIB

ind-span-a51797e23258b20301f2

label id

5b2d0f4e-5bba-4048-a2f0-bcb4b779efc0

positive predicate support span

end: 66
end exclusive: true
exact text: is a kinase inhibitor indicated
label id: 5b2d0f4e-5bba-4048-a2f0-bcb4b779efc0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f68ed7c4d30314c0e63657bc67b4f9a830de4cb553a2492a05e9ea160d7e4e27
start: 35

qualifier mentions

context exact
en or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth
kind
age
polarity
not_inferred
span
end
188
end exclusive
true
exact text
adult patients
label id
5b2d0f4e-5bba-4048-a2f0-bcb4b779efc0
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f68ed7c4d30314c0e63657bc67b4f9a830de4cb553a2492a05e9ea160d7e4e27
start
174
context exact
or (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of recurre
kind
biomarker
polarity
not_inferred
span
end
282
end exclusive
true
exact text
HER2)-negative
label id
5b2d0f4e-5bba-4048-a2f0-bcb4b779efc0
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f68ed7c4d30314c0e63657bc67b4f9a830de4cb553a2492a05e9ea160d7e4e27
start
268
context exact
crine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor
kind
stage_or_setting
polarity
not_inferred
span
end
195
end exclusive
true
exact text
adjuvant treatment of adult patients with h
label id
5b2d0f4e-5bba-4048-a2f0-bcb4b779efc0
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f68ed7c4d30314c0e63657bc67b4f9a830de4cb553a2492a05e9ea160d7e4e27
start
152
context exact
TIONS AND USAGE VERZENIO ® is a kinase inhibitor indicated: in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early br
kind
regimen
polarity
not_inferred
span
end
247
end exclusive
true
exact text
in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growt
label id
5b2d0f4e-5bba-4048-a2f0-bcb4b779efc0
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f68ed7c4d30314c0e63657bc67b4f9a830de4cb553a2492a05e9ea160d7e4e27
start
68

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

source span

end: 346
end exclusive: true
exact text: 1 INDICATIONS AND USAGE VERZENIO ® is a kinase inhibitor indicated: in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of recurrence.
label id: 5b2d0f4e-5bba-4048-a2f0-bcb4b779efc0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f68ed7c4d30314c0e63657bc67b4f9a830de4cb553a2492a05e9ea160d7e4e27
start: 0

source url

https://api.fda.gov/drug/label.json?search=id%3A%225b2d0f4e-5bba-4048-a2f0-bcb4b779efc0%22

spl effective date

2026-07-13

spl set id

be4bc0de-0fdc-4d46-8d25-be43c79e6a06

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 2 · positive indication candidate

application numbers

NDA208716

brand names

Verzenio

classification reasons

inherited_predicate_from_same_label_section_requires_review
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 807
end exclusive: true
exact text: the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of recurrence. ( 1.1 , 14.1 ) in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. ( 1.2 ) in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast
label id: 5b2d0f4e-5bba-4048-a2f0-bcb4b779efc0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f68ed7c4d30314c0e63657bc67b4f9a830de4cb553a2492a05e9ea160d7e4e27
start: 147

current approval status

not_reconciled

duplicate text group

dup-a1514ab03a60639c79ea

extraction review status

automated_candidate_pending_source_review

generic names

ABEMACICLIB

ind-span-4bdd1d8b7a910e5ad131

label id

5b2d0f4e-5bba-4048-a2f0-bcb4b779efc0

positive predicate support span

end: 66
end exclusive: true
exact text: is a kinase inhibitor indicated
label id: 5b2d0f4e-5bba-4048-a2f0-bcb4b779efc0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f68ed7c4d30314c0e63657bc67b4f9a830de4cb553a2492a05e9ea160d7e4e27
start: 35

qualifier mentions

context exact
tor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth
kind
age
polarity
not_inferred
span
end
475
end exclusive
true
exact text
adult patients
label id
5b2d0f4e-5bba-4048-a2f0-bcb4b779efc0
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f68ed7c4d30314c0e63657bc67b4f9a830de4cb553a2492a05e9ea160d7e4e27
start
461
context exact
or (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.
kind
biomarker
polarity
not_inferred
span
end
599
end exclusive
true
exact text
HER2)-negative advanced or metastatic breast
label id
5b2d0f4e-5bba-4048-a2f0-bcb4b779efc0
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f68ed7c4d30314c0e63657bc67b4f9a830de4cb553a2492a05e9ea160d7e4e27
start
555
context exact
e, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.
kind
stage_or_setting
polarity
not_inferred
span
end
606
end exclusive
true
exact text
advanced or metastatic breast cancer
label id
5b2d0f4e-5bba-4048-a2f0-bcb4b779efc0
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f68ed7c4d30314c0e63657bc67b4f9a830de4cb553a2492a05e9ea160d7e4e27
start
570
context exact
( 1.1 , 14.1 ) in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast c
kind
regimen
polarity
not_inferred
span
end
541
end exclusive
true
exact text
in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth facto
label id
5b2d0f4e-5bba-4048-a2f0-bcb4b779efc0
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f68ed7c4d30314c0e63657bc67b4f9a830de4cb553a2492a05e9ea160d7e4e27
start
362

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

source span

end: 607
end exclusive: true
exact text: ( 1.1 , 14.1 ) in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.
label id: 5b2d0f4e-5bba-4048-a2f0-bcb4b779efc0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f68ed7c4d30314c0e63657bc67b4f9a830de4cb553a2492a05e9ea160d7e4e27
start: 347

source url

https://api.fda.gov/drug/label.json?search=id%3A%225b2d0f4e-5bba-4048-a2f0-bcb4b779efc0%22

spl effective date

2026-07-13

spl set id

be4bc0de-0fdc-4d46-8d25-be43c79e6a06

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 3 · unclassified context

application numbers

NDA208716

brand names

Verzenio

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 815
end exclusive: true
exact text: initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. ( 1.2 ) in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer
label id: 5b2d0f4e-5bba-4048-a2f0-bcb4b779efc0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f68ed7c4d30314c0e63657bc67b4f9a830de4cb553a2492a05e9ea160d7e4e27
start: 408

current approval status

not_reconciled

duplicate text group

dup-838ef2037722dbba8cac

extraction review status

automated_candidate_pending_source_review

generic names

ABEMACICLIB

ind-span-cb9f88a10dc4dc99037a

label id

5b2d0f4e-5bba-4048-a2f0-bcb4b779efc0

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

source span

end: 615
end exclusive: true
exact text: ( 1.2 )
label id: 5b2d0f4e-5bba-4048-a2f0-bcb4b779efc0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f68ed7c4d30314c0e63657bc67b4f9a830de4cb553a2492a05e9ea160d7e4e27
start: 608

source url

https://api.fda.gov/drug/label.json?search=id%3A%225b2d0f4e-5bba-4048-a2f0-bcb4b779efc0%22

spl effective date

2026-07-13

spl set id

be4bc0de-0fdc-4d46-8d25-be43c79e6a06

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 4 · positive indication candidate

application numbers

NDA208716

brand names

Verzenio

classification reasons

inherited_predicate_from_same_label_section_requires_review
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1068
end exclusive: true
exact text: endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. ( 1.2 ) in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. ( 1.2 ) as monotherapy for the treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemothe
label id: 5b2d0f4e-5bba-4048-a2f0-bcb4b779efc0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f68ed7c4d30314c0e63657bc67b4f9a830de4cb553a2492a05e9ea160d7e4e27
start: 416

current approval status

not_reconciled

duplicate text group

dup-51494e367ef3ef6171ad

extraction review status

automated_candidate_pending_source_review

generic names

ABEMACICLIB

ind-span-33b9b506d39a977a232c

label id

5b2d0f4e-5bba-4048-a2f0-bcb4b779efc0

positive predicate support span

end: 66
end exclusive: true
exact text: is a kinase inhibitor indicated
label id: 5b2d0f4e-5bba-4048-a2f0-bcb4b779efc0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f68ed7c4d30314c0e63657bc67b4f9a830de4cb553a2492a05e9ea160d7e4e27
start: 35

qualifier mentions

context exact
in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth
kind
age
polarity
not_inferred
span
end
683
end exclusive
true
exact text
adult patients
label id
5b2d0f4e-5bba-4048-a2f0-bcb4b779efc0
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f68ed7c4d30314c0e63657bc67b4f9a830de4cb553a2492a05e9ea160d7e4e27
start
669
context exact
or (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy
kind
biomarker
polarity
not_inferred
span
end
807
end exclusive
true
exact text
HER2)-negative advanced or metastatic breast
label id
5b2d0f4e-5bba-4048-a2f0-bcb4b779efc0
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f68ed7c4d30314c0e63657bc67b4f9a830de4cb553a2492a05e9ea160d7e4e27
start
763
context exact
e, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy.
kind
stage_or_setting
polarity
not_inferred
span
end
821
end exclusive
true
exact text
advanced or metastatic breast cancer with d
label id
5b2d0f4e-5bba-4048-a2f0-bcb4b779efc0
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f68ed7c4d30314c0e63657bc67b4f9a830de4cb553a2492a05e9ea160d7e4e27
start
778
context exact
in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endoc
kind
regimen
polarity
not_inferred
span
end
795
end exclusive
true
exact text
in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metas
label id
5b2d0f4e-5bba-4048-a2f0-bcb4b779efc0
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f68ed7c4d30314c0e63657bc67b4f9a830de4cb553a2492a05e9ea160d7e4e27
start
616

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

source span

end: 868
end exclusive: true
exact text: in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy.
label id: 5b2d0f4e-5bba-4048-a2f0-bcb4b779efc0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f68ed7c4d30314c0e63657bc67b4f9a830de4cb553a2492a05e9ea160d7e4e27
start: 616

source url

https://api.fda.gov/drug/label.json?search=id%3A%225b2d0f4e-5bba-4048-a2f0-bcb4b779efc0%22

spl effective date

2026-07-13

spl set id

be4bc0de-0fdc-4d46-8d25-be43c79e6a06

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 5 · unclassified context

application numbers

NDA208716

brand names

Verzenio

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1076
end exclusive: true
exact text: adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. ( 1.2 ) as monotherapy for the treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in
label id: 5b2d0f4e-5bba-4048-a2f0-bcb4b779efc0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f68ed7c4d30314c0e63657bc67b4f9a830de4cb553a2492a05e9ea160d7e4e27
start: 669

current approval status

not_reconciled

duplicate text group

dup-838ef2037722dbba8cac

extraction review status

automated_candidate_pending_source_review

generic names

ABEMACICLIB

ind-span-45022d01fd2c30d133d1

label id

5b2d0f4e-5bba-4048-a2f0-bcb4b779efc0

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

source span

end: 876
end exclusive: true
exact text: ( 1.2 )
label id: 5b2d0f4e-5bba-4048-a2f0-bcb4b779efc0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f68ed7c4d30314c0e63657bc67b4f9a830de4cb553a2492a05e9ea160d7e4e27
start: 869

source url

https://api.fda.gov/drug/label.json?search=id%3A%225b2d0f4e-5bba-4048-a2f0-bcb4b779efc0%22

spl effective date

2026-07-13

spl set id

be4bc0de-0fdc-4d46-8d25-be43c79e6a06

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 6 · unclassified context

application numbers

NDA208716

brand names

Verzenio

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1299
end exclusive: true
exact text: tients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. ( 1.2 ) as monotherapy for the treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting. ( 1.2 ) 1.1 Early Breast Cancer VERZENIO ® (abemaciclib) is indicated: in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with ho
label id: 5b2d0f4e-5bba-4048-a2f0-bcb4b779efc0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f68ed7c4d30314c0e63657bc67b4f9a830de4cb553a2492a05e9ea160d7e4e27
start: 677

current approval status

not_reconciled

duplicate text group

dup-944d197a9763d033be8c

extraction review status

automated_candidate_pending_source_review

generic names

ABEMACICLIB

ind-span-fcdaa49f1f949c3d89dd

label id

5b2d0f4e-5bba-4048-a2f0-bcb4b779efc0

positive predicate support span

Source null

qualifier mentions

context exact
as monotherapy for the treatment of adult patients with HR-positive, HER2-negative advanced or metastatic brea
kind
age
polarity
not_inferred
span
end
927
end exclusive
true
exact text
adult patients
label id
5b2d0f4e-5bba-4048-a2f0-bcb4b779efc0
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f68ed7c4d30314c0e63657bc67b4f9a830de4cb553a2492a05e9ea160d7e4e27
start
913
context exact
erapy for the treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy
kind
biomarker
polarity
not_inferred
span
end
990
end exclusive
true
exact text
HER2-negative advanced or metastatic breast
label id
5b2d0f4e-5bba-4048-a2f0-bcb4b779efc0
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f68ed7c4d30314c0e63657bc67b4f9a830de4cb553a2492a05e9ea160d7e4e27
start
946
context exact
n following endocrine therapy and prior chemotherapy in the metastatic setting.
kind
biomarker
polarity
not_inferred
span
end
1098
end exclusive
true
exact text
metastatic setting
label id
5b2d0f4e-5bba-4048-a2f0-bcb4b779efc0
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f68ed7c4d30314c0e63657bc67b4f9a830de4cb553a2492a05e9ea160d7e4e27
start
1080
context exact
treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior che
kind
stage_or_setting
polarity
not_inferred
span
end
1003
end exclusive
true
exact text
advanced or metastatic breast cancer with d
label id
5b2d0f4e-5bba-4048-a2f0-bcb4b779efc0
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f68ed7c4d30314c0e63657bc67b4f9a830de4cb553a2492a05e9ea160d7e4e27
start
960
context exact
n following endocrine therapy and prior chemotherapy in the metastatic setting.
kind
stage_or_setting
polarity
not_inferred
span
end
1098
end exclusive
true
exact text
metastatic setting
label id
5b2d0f4e-5bba-4048-a2f0-bcb4b779efc0
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f68ed7c4d30314c0e63657bc67b4f9a830de4cb553a2492a05e9ea160d7e4e27
start
1080
context exact
as monotherapy for the treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.
kind
regimen
polarity
not_inferred
span
end
1051
end exclusive
true
exact text
as monotherapy for the treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy a
label id
5b2d0f4e-5bba-4048-a2f0-bcb4b779efc0
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f68ed7c4d30314c0e63657bc67b4f9a830de4cb553a2492a05e9ea160d7e4e27
start
877

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

source span

end: 1099
end exclusive: true
exact text: as monotherapy for the treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.
label id: 5b2d0f4e-5bba-4048-a2f0-bcb4b779efc0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f68ed7c4d30314c0e63657bc67b4f9a830de4cb553a2492a05e9ea160d7e4e27
start: 877

source url

https://api.fda.gov/drug/label.json?search=id%3A%225b2d0f4e-5bba-4048-a2f0-bcb4b779efc0%22

spl effective date

2026-07-13

spl set id

be4bc0de-0fdc-4d46-8d25-be43c79e6a06

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 7 · unclassified context

application numbers

NDA208716

brand names

Verzenio

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1307
end exclusive: true
exact text: treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting. ( 1.2 ) 1.1 Early Breast Cancer VERZENIO ® (abemaciclib) is indicated: in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone re
label id: 5b2d0f4e-5bba-4048-a2f0-bcb4b779efc0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f68ed7c4d30314c0e63657bc67b4f9a830de4cb553a2492a05e9ea160d7e4e27
start: 900

current approval status

not_reconciled

duplicate text group

dup-838ef2037722dbba8cac

extraction review status

automated_candidate_pending_source_review

generic names

ABEMACICLIB

ind-span-e992a1b40fa59ef40df3

label id

5b2d0f4e-5bba-4048-a2f0-bcb4b779efc0

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

source span

end: 1107
end exclusive: true
exact text: ( 1.2 )
label id: 5b2d0f4e-5bba-4048-a2f0-bcb4b779efc0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f68ed7c4d30314c0e63657bc67b4f9a830de4cb553a2492a05e9ea160d7e4e27
start: 1100

source url

https://api.fda.gov/drug/label.json?search=id%3A%225b2d0f4e-5bba-4048-a2f0-bcb4b779efc0%22

spl effective date

2026-07-13

spl set id

be4bc0de-0fdc-4d46-8d25-be43c79e6a06

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 8 · positive indication candidate

application numbers

NDA208716

brand names

Verzenio

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement
positive_statement_also_contains_qualification_review_required

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1681
end exclusive: true
exact text: t of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting. ( 1.2 ) 1.1 Early Breast Cancer VERZENIO ® (abemaciclib) is indicated: in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of recurrence [see Clinical Studies ( 14.1 )]. 1.2 Advanced or Metastatic Breast Cancer VERZENIO (abemaciclib) is indicated: in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with ho
label id: 5b2d0f4e-5bba-4048-a2f0-bcb4b779efc0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f68ed7c4d30314c0e63657bc67b4f9a830de4cb553a2492a05e9ea160d7e4e27
start: 908

current approval status

not_reconciled

duplicate text group

dup-6cefa823225c43968a23

extraction review status

automated_candidate_pending_source_review

generic names

ABEMACICLIB

ind-span-f3f704fd6973f46f61f7

label id

5b2d0f4e-5bba-4048-a2f0-bcb4b779efc0

positive predicate support span

end: 1169
end exclusive: true
exact text: is indicated
label id: 5b2d0f4e-5bba-4048-a2f0-bcb4b779efc0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f68ed7c4d30314c0e63657bc67b4f9a830de4cb553a2492a05e9ea160d7e4e27
start: 1157

qualifier mentions

context exact
en or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth
kind
age
polarity
not_inferred
span
end
1291
end exclusive
true
exact text
adult patients
label id
5b2d0f4e-5bba-4048-a2f0-bcb4b779efc0
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f68ed7c4d30314c0e63657bc67b4f9a830de4cb553a2492a05e9ea160d7e4e27
start
1277
context exact
or (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of recurre
kind
biomarker
polarity
not_inferred
span
end
1385
end exclusive
true
exact text
HER2)-negative
label id
5b2d0f4e-5bba-4048-a2f0-bcb4b779efc0
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f68ed7c4d30314c0e63657bc67b4f9a830de4cb553a2492a05e9ea160d7e4e27
start
1371
context exact
crine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor
kind
stage_or_setting
polarity
not_inferred
span
end
1298
end exclusive
true
exact text
adjuvant treatment of adult patients with h
label id
5b2d0f4e-5bba-4048-a2f0-bcb4b779efc0
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f68ed7c4d30314c0e63657bc67b4f9a830de4cb553a2492a05e9ea160d7e4e27
start
1255
context exact
Early Breast Cancer VERZENIO ® (abemaciclib) is indicated: in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early br
kind
regimen
polarity
not_inferred
span
end
1350
end exclusive
true
exact text
in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growt
label id
5b2d0f4e-5bba-4048-a2f0-bcb4b779efc0
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f68ed7c4d30314c0e63657bc67b4f9a830de4cb553a2492a05e9ea160d7e4e27
start
1171

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

source span

end: 1481
end exclusive: true
exact text: 1.1 Early Breast Cancer VERZENIO ® (abemaciclib) is indicated: in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of recurrence [see Clinical Studies ( 14.1 )].
label id: 5b2d0f4e-5bba-4048-a2f0-bcb4b779efc0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f68ed7c4d30314c0e63657bc67b4f9a830de4cb553a2492a05e9ea160d7e4e27
start: 1108

source url

https://api.fda.gov/drug/label.json?search=id%3A%225b2d0f4e-5bba-4048-a2f0-bcb4b779efc0%22

spl effective date

2026-07-13

spl set id

be4bc0de-0fdc-4d46-8d25-be43c79e6a06

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 9 · positive indication candidate

application numbers

NDA208716

brand names

Verzenio

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2281
end exclusive: true
exact text: patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of recurrence [see Clinical Studies ( 14.1 )]. 1.2 Advanced or Metastatic Breast Cancer VERZENIO (abemaciclib) is indicated: in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. as monotherapy for the treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.
label id: 5b2d0f4e-5bba-4048-a2f0-bcb4b779efc0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f68ed7c4d30314c0e63657bc67b4f9a830de4cb553a2492a05e9ea160d7e4e27
start: 1282

current approval status

not_reconciled

duplicate text group

dup-8a73d48202a6b7af3a27

extraction review status

automated_candidate_pending_source_review

generic names

ABEMACICLIB

ind-span-1cdcc020039921655a8c

label id

5b2d0f4e-5bba-4048-a2f0-bcb4b779efc0

positive predicate support span

end: 1558
end exclusive: true
exact text: is indicated
label id: 5b2d0f4e-5bba-4048-a2f0-bcb4b779efc0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f68ed7c4d30314c0e63657bc67b4f9a830de4cb553a2492a05e9ea160d7e4e27
start: 1546

qualifier mentions

context exact
tor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth
kind
age
polarity
not_inferred
span
end
1673
end exclusive
true
exact text
adult patients
label id
5b2d0f4e-5bba-4048-a2f0-bcb4b779efc0
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f68ed7c4d30314c0e63657bc67b4f9a830de4cb553a2492a05e9ea160d7e4e27
start
1659
context exact
ancer. in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth
kind
age
polarity
not_inferred
span
end
1873
end exclusive
true
exact text
adult patients
label id
5b2d0f4e-5bba-4048-a2f0-bcb4b779efc0
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f68ed7c4d30314c0e63657bc67b4f9a830de4cb553a2492a05e9ea160d7e4e27
start
1859
context exact
wing endocrine therapy. as monotherapy for the treatment of adult patients with HR-positive, HER2-negative advanced or metastatic brea
kind
age
polarity
not_inferred
span
end
2109
end exclusive
true
exact text
adult patients
label id
5b2d0f4e-5bba-4048-a2f0-bcb4b779efc0
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f68ed7c4d30314c0e63657bc67b4f9a830de4cb553a2492a05e9ea160d7e4e27
start
2095
context exact
1.2 Advanced or Metastatic Breast Cancer VERZENIO (abemaciclib) is indicated: in combination with an aromatase inhibito
kind
biomarker
polarity
not_inferred
span
end
1541
end exclusive
true
exact text
Metastatic Breast Cancer VERZENIO (abemacic
label id
5b2d0f4e-5bba-4048-a2f0-bcb4b779efc0
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f68ed7c4d30314c0e63657bc67b4f9a830de4cb553a2492a05e9ea160d7e4e27
start
1498
context exact
or (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. in combination with fulvestrant for the treatment o
kind
biomarker
polarity
not_inferred
span
end
1797
end exclusive
true
exact text
HER2)-negative advanced or metastatic breast
label id
5b2d0f4e-5bba-4048-a2f0-bcb4b779efc0
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f68ed7c4d30314c0e63657bc67b4f9a830de4cb553a2492a05e9ea160d7e4e27
start
1753
context exact
or (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy
kind
biomarker
polarity
not_inferred
span
end
1997
end exclusive
true
exact text
HER2)-negative advanced or metastatic breast
label id
5b2d0f4e-5bba-4048-a2f0-bcb4b779efc0
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f68ed7c4d30314c0e63657bc67b4f9a830de4cb553a2492a05e9ea160d7e4e27
start
1953
context exact
erapy for the treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy
kind
biomarker
polarity
not_inferred
span
end
2172
end exclusive
true
exact text
HER2-negative advanced or metastatic breast
label id
5b2d0f4e-5bba-4048-a2f0-bcb4b779efc0
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f68ed7c4d30314c0e63657bc67b4f9a830de4cb553a2492a05e9ea160d7e4e27
start
2128
context exact
n following endocrine therapy and prior chemotherapy in the metastatic setting.
kind
biomarker
polarity
not_inferred
span
end
2280
end exclusive
true
exact text
metastatic setting
label id
5b2d0f4e-5bba-4048-a2f0-bcb4b779efc0
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f68ed7c4d30314c0e63657bc67b4f9a830de4cb553a2492a05e9ea160d7e4e27
start
2262
context exact
1.2 Advanced or Metastatic Breast Cancer VERZENIO (abemaciclib) is indicated: in combination with an aromat
kind
stage_or_setting
polarity
not_inferred
span
end
1529
end exclusive
true
exact text
Advanced or Metastatic Breast Cancer VERZEN
label id
5b2d0f4e-5bba-4048-a2f0-bcb4b779efc0
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f68ed7c4d30314c0e63657bc67b4f9a830de4cb553a2492a05e9ea160d7e4e27
start
1486
context exact
e, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. in combination with fulvestrant for the treatment of adult
kind
stage_or_setting
polarity
not_inferred
span
end
1804
end exclusive
true
exact text
advanced or metastatic breast cancer
label id
5b2d0f4e-5bba-4048-a2f0-bcb4b779efc0
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f68ed7c4d30314c0e63657bc67b4f9a830de4cb553a2492a05e9ea160d7e4e27
start
1768
context exact
e, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. as monothera
kind
stage_or_setting
polarity
not_inferred
span
end
2011
end exclusive
true
exact text
advanced or metastatic breast cancer with d
label id
5b2d0f4e-5bba-4048-a2f0-bcb4b779efc0
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f68ed7c4d30314c0e63657bc67b4f9a830de4cb553a2492a05e9ea160d7e4e27
start
1968
context exact
treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior che
kind
stage_or_setting
polarity
not_inferred
span
end
2185
end exclusive
true
exact text
advanced or metastatic breast cancer with d
label id
5b2d0f4e-5bba-4048-a2f0-bcb4b779efc0
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f68ed7c4d30314c0e63657bc67b4f9a830de4cb553a2492a05e9ea160d7e4e27
start
2142

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

source span

end: 2281
end exclusive: true
exact text: 1.2 Advanced or Metastatic Breast Cancer VERZENIO (abemaciclib) is indicated: in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. as monotherapy for the treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.
label id: 5b2d0f4e-5bba-4048-a2f0-bcb4b779efc0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f68ed7c4d30314c0e63657bc67b4f9a830de4cb553a2492a05e9ea160d7e4e27
start: 1482

source url

https://api.fda.gov/drug/label.json?search=id%3A%225b2d0f4e-5bba-4048-a2f0-bcb4b779efc0%22

spl effective date

2026-07-13

spl set id

be4bc0de-0fdc-4d46-8d25-be43c79e6a06

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Preserved source evidence · Not medical advice